Floatz logo

RIFALDAZINE

Cystic Fibrosis

Johns Hopkins UniversitySmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
73/ 100

Competitive context

82 Active assets in the Cystic Fibrosis cohort.

Asset / SponsorPhaseRating
Tezacaftor
Vertex Pharmaceuticals Incorporated
Phase 4A
Liprotamase
Anthera Pharmaceuticals
Phase 4BBB
Ivacaftor
Meyer Children's Hospital IRCCS
Phase 4BBB
Lumacaftor
Hospices Civils de Lyon
Phase 4BBB
ELEXACAFTOR
Meyer Children's Hospital IRCCS
Phase 4BBB

View all 50 →

Same molecule, other indications

RIFALDAZINE is also rated in:

methicillin-resistant staphylococcus aureus infectious diseaseDormant
BB
Indicative ·
71 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
B
Indicative ·
62 / 100
View asset →
Alzheimer diseaseDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →